---
schema_version: "secwatch.filing_event.v1"
accession: "0001867096-26-000012"
form_type: "8-K"
ticker: "XERS"
cik: "0001867096"
company_name: "Xeris Biopharma Holdings, Inc."
filed_at: "2026-03-02T23:59:59+00:00"
generated_at: "2026-05-15T22:47:17.802560+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Xeris Biopharma reports record Q4 revenue $85.8M (+43% YoY); net income $11.1M, provides FY2026 guidance $375-390M

## Summary
- Q4 total revenue $85.8M (+42.8% YoY); net income $11.1M vs net loss $5.1M in Q4 2024.
- Recorlev Q4 revenue $45.3M (+100% YoY); FY2025 total revenue $291.8M (+43.7% YoY).
- FY2026 total revenue guidance $375M-$390M, >30% growth at midpoint.
- Adjusted EBITDA Q4 $25.1M, improvement of $16.8M vs prior year.
- Company expects timely execution of XP-8121 Phase 3 trial; remains focused on capital deployment.

## SEC filing metadata
- accession: 0001867096-26-000012
- form_type: 8-K
- ticker: XERS
- cik: 0001867096
- company_name: Xeris Biopharma Holdings, Inc.
- filed_at: 2026-03-02T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1867096/000186709626000012/0001867096-26-000012-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1867096/000186709626000012/xers-20260302.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001867096-26-000012
- JSON: https://secwatch.observer/filing/0001867096-26-000012.json
- Plain text: https://secwatch.observer/filing/0001867096-26-000012.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.